Oligonucleotide therapy: An emerging focus area for drug delivery in chronic inflammatory respiratory diseases.

Dendrimers / chemistry Drug Carriers / chemistry Humans Liposomes / chemistry MicroRNAs / chemistry Nanoparticles / chemistry Oligonucleotides, Antisense / chemistry Pulmonary Disease, Chronic Obstructive / drug therapy RNA Interference RNA, Small Interfering / chemistry
Nano-drug delivery Novel approaches Oligonucleotides Respiratory diseases miRNA siRNA

Journal

Chemico-biological interactions
ISSN: 1872-7786
Titre abrégé: Chem Biol Interact
Pays: Ireland
ID NLM: 0227276

Informations de publication

Date de publication:
01 Aug 2019
Historique:
received: 05 04 2019
revised: 30 04 2019
accepted: 15 05 2019
pubmed: 29 5 2019
medline: 23 7 2019
entrez: 29 5 2019
Statut: ppublish

Résumé

Oligonucleotide-based therapies are advanced novel interventions used in the management of various respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). These agents primarily act by gene silencing or RNA interference. Better methodologies and techniques are the need of the hour that can deliver these agents to tissues and cells in a target specific manner by which their maximum potential can be reached in the management of chronic inflammatory diseases. Nanoparticles play an important role in the target-specific delivery of drugs. In addition, oligonucleotides also are extensively used for gene transfer in the form of polymeric, liposomal and inorganic carrier materials. Therefore, the current review focuses on various novel dosage forms like nanoparticles, liposomes that can be used efficiently for the delivery of various oligonucleotides such as siRNA and miRNA. We also discuss the future perspectives and targets for oligonucleotides in the management of respiratory diseases.

Identifiants

DOI: 10.1016/j.cbi.2019.05.028 PMID: 31136735 PMC: PMC7094617
pubmed: 31136735
pii: S0009-2797(19)30575-7
doi: 10.1016/j.cbi.2019.05.028
pmc: PMC7094617
pii:
doi:

Substances chimiques

Dendrimers 0
Drug Carriers 0
Liposomes 0
MicroRNAs 0
Oligonucleotides, Antisense 0
RNA, Small Interfering 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

206-215

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Références

Future Med Chem. 2011 Oct;3(13):1647-62
pubmed: 21942254
Int J Mol Sci. 2014 Apr 08;15(4):5852-73
pubmed: 24717409
Eur J Pharm Biopharm. 2012 Apr;80(3):478-89
pubmed: 22198416
AAPS J. 2014 Sep;16(5):975-85
pubmed: 24981892
Nat Rev Neurol. 2018 Jan;14(1):9-21
pubmed: 29192260
Drug Deliv Transl Res. 2017 Feb;7(1):168-178
pubmed: 27848224
Arthritis Res Ther. 2010;12(2):R60
pubmed: 20359365
Oligonucleotides. 2009 Jun;19(2):163-8
pubmed: 19441893
Pharm Nanotechnol. 2017;5(4):243-249
pubmed: 28786352
Biomaterials. 2007 Feb;28(6):1280-8
pubmed: 17126901
Acc Chem Res. 2012 Jul 17;45(7):961-70
pubmed: 21905687
Mol Pharm. 2014 Jun 2;11(6):1808-22
pubmed: 24811243
J Control Release. 2016 May 10;229:120-129
pubmed: 27001893
Eur J Pharm Biopharm. 2004 Jul;58(1):1-6
pubmed: 15207531
J Drug Target. 2012 Nov;20(9):724-35
pubmed: 22994300
Nat Med. 2005 Jan;11(1):56-62
pubmed: 15619625
Curr Opin Pharmacol. 2015 Oct;24:52-8
pubmed: 26277332
Chem Biol Interact. 2019 Feb 1;299:168-178
pubmed: 30553721
Infect Immun. 2000 Oct;68(10):5764-70
pubmed: 10992483
J Clin Invest. 2011 Feb;121(2):500-7
pubmed: 21285523
Am J Respir Crit Care Med. 2008 Jul 1;178(1):60-73
pubmed: 18310482
J Biol Chem. 2016 Mar 18;291(12):6433-46
pubmed: 26817844
Proc Natl Acad Sci U S A. 1978 Jan;75(1):280-4
pubmed: 75545
Vaccine. 2003 Mar 28;21(13-14):1478-85
pubmed: 12615444
J Drug Target. 2019 Feb;27(2):217-227
pubmed: 30024300
Eur J Biochem. 2003 Apr;270(8):1628-44
pubmed: 12694176
Mol Pharm. 2015 Mar 2;12(3):826-38
pubmed: 25455560
J Control Release. 1998 Apr 30;53(1-3):183-93
pubmed: 9741926
Gene Ther. 2001 Jul;8(14):1108-21
pubmed: 11526458
Molecules. 2017 Jan 17;22(1):
pubmed: 28106744
Nature. 2005 Dec 1;438(7068):685-9
pubmed: 16258535
Nat Biotechnol. 1999 Jun;17(6):583-7
pubmed: 10385324
Respir Res. 2001;2(1):5-9
pubmed: 11686859
Sensors (Basel). 2012;12(1):612-31
pubmed: 22368488
Expert Opin Biol Ther. 2007 Dec;7(12):1811-22
pubmed: 18034647
Biologics. 2007 Sep;1(3):271-83
pubmed: 19707336
Biomaterials. 2013 Oct;34(31):7744-53
pubmed: 23850099
Eur J Immunol. 2005 Jun;35(6):1869-76
pubmed: 15909311
J Adv Pharm Technol Res. 2010 Oct;1(4):374-80
pubmed: 22247876
J Immunol. 2001 Sep 15;167(6):3324-8
pubmed: 11544321
Respir Res. 2015 May 29;16:64
pubmed: 26021823
Eur J Endocrinol. 2018 Aug;179(2):97-108
pubmed: 29789410
Vaccines (Basel). 2015 May 08;3(2):390-407
pubmed: 26343193
Mol Ther Nucleic Acids. 2013 Jun 04;2:e96
pubmed: 23736774
Curr Opin Pharmacol. 2008 Jun;8(3):280-5
pubmed: 18485820
Pharmaceutics. 2019 Jan 29;11(2):
pubmed: 30700021
Genet Vaccines Ther. 2008 Feb 15;6:7
pubmed: 18279512
Biomed Pharmacother. 2018 Nov;107:1218-1229
pubmed: 30257336
Exp Lung Res. 2017 Aug - Sep;43(6-7):271-282
pubmed: 29035148
J Diabetes Sci Technol. 2009 Jul 01;3(4):924-30
pubmed: 20144342
ACS Nano. 2010 Jul 27;4(7):3591-605
pubmed: 20568710
Expert Opin Drug Deliv. 2008 Jun;5(6):629-39
pubmed: 18532919
J Immunol. 1998 Mar 15;160(6):2555-9
pubmed: 9510150
Ann N Y Acad Sci. 2006 Oct;1082:62-73
pubmed: 17145927
Nat Rev Drug Discov. 2012 Jan 20;11(2):125-40
pubmed: 22262036
Expert Opin Investig Drugs. 2009 Oct;18(10):1505-17
pubmed: 19715448
Interv Med Appl Sci. 2017 Mar;9(1):39-41
pubmed: 28932494
Lancet. 2012 Aug 18;380(9842):651-9
pubmed: 22901886
Vaccine. 1999 Oct 14;18(5-6):558-67
pubmed: 10519947
Biomaterials. 2017 Nov;145:56-71
pubmed: 28843733
Int J Pharm Investig. 2012 Jan;2(1):2-11
pubmed: 23071954
J Med Chem. 2014 Oct 23;57(20):8332-9
pubmed: 25249262
J Control Release. 2000 Nov 3;69(2):309-22
pubmed: 11064137
J Clin Microbiol. 2004 Sep;42(9):4268-74
pubmed: 15365022
J Control Release. 2001 Jul 10;75(1-2):211-24
pubmed: 11451511
J Intern Med. 2010 Jan;267(1):44-53
pubmed: 20059643
Mater Sci Eng C Mater Biol Appl. 2017 Nov 1;80:771-784
pubmed: 28866227
Nucleic Acids Res. 2016 Aug 19;44(14):6518-48
pubmed: 27084936
J Clin Microbiol. 2004 Jul;42(7):3232-9
pubmed: 15243087
Biochim Biophys Acta. 2010 Nov;1803(11):1231-43
pubmed: 20619301
Acta Biomater. 2017 Jan 1;47:71-80
pubmed: 27697601
Adv Healthc Mater. 2013 Apr;2(4):576-84
pubmed: 23184673
Eur J Pharm Sci. 2005 Jul-Aug;25(4-5):427-37
pubmed: 15893461
Adv Drug Deliv Rev. 2015 Jun 29;87:35-45
pubmed: 25881722
Molecules. 2016 Sep 20;21(9):
pubmed: 27657028
RNA Biol. 2018;15(6):707-714
pubmed: 29560813
Eur J Pharm Biopharm. 2018 Sep;130:30-38
pubmed: 29890256
Front Chem. 2014 Oct 14;2:87
pubmed: 25353019
Bioorg Med Chem Lett. 2004 Mar 8;14(5):1139-43
pubmed: 14980652
J Drug Target. 2011 Dec;19(10):900-14
pubmed: 21981718
Genet Vaccines Ther. 2007 Feb 01;5:4
pubmed: 17270047
Adv Drug Deliv Rev. 2018 Sep;134:3-21
pubmed: 29626546
Chem Biol Interact. 2019 May 1;304:10-19
pubmed: 30849336
Mol Pharm. 2012 Apr 2;9(4):946-56
pubmed: 22356166
Mol Ther. 2006 Oct;14(4):476-84
pubmed: 16829204
J Control Release. 2018 Sep 10;285:35-45
pubmed: 30004000
J Support Oncol. 2007 Oct;5(9):451-7
pubmed: 18019853
Pharm Res. 2009 Feb;26(2):382-94
pubmed: 18958402
Mol Ther. 2017 May 3;25(5):1069-1075
pubmed: 28366767
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):3095-101
pubmed: 17048523
Annu Rev Biomed Eng. 2006;8:377-402
pubmed: 16834561
Int J Nanomedicine. 2008;3(1):1-19
pubmed: 18488412
Adv Drug Deliv Rev. 2001 Dec 31;53(3):341-58
pubmed: 11744176
J Cyst Fibros. 2019 Jul;18(4):536-542
pubmed: 30467074
Vaccine. 2004 Apr 16;22(13-14):1609-15
pubmed: 15068842
Int J Pharm. 2009 May 8;372(1-2):97-104
pubmed: 19429272
Nano Lett. 2015 May 13;15(5):3008-16
pubmed: 25789998
J Control Release. 2013 Nov 10;171(3):349-57
pubmed: 23648833
Molecules. 2018 Aug 31;23(9):
pubmed: 30200314
Genet Vaccines Ther. 2003 Oct 27;1(1):3
pubmed: 14613519
J Control Release. 2001 Feb 23;70(3):399-421
pubmed: 11182210
Biomaterials. 2013 Jan;34(4):1261-9
pubmed: 23102621
Mol Ther Nucleic Acids. 2015 Sep 15;4:e252
pubmed: 26372022

Auteurs

Meenu Mehta (M)

School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India.
School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India.

Devesh Tewari (D)

School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India.

Gaurav Gupta (G)

School of Phamacy, Suresh Gyan Vihar University, Jagatpura, Mahal Road, Jaipur, India.

Rajendra Awasthi (R)

Amity School of Pharmacy, Amity University, Noida, Uttar Pradesh, India.

Harjeet Singh (H)

National Medicinal Plants Board, Ministry of AYUSH, New Delhi, India.

Parijat Pandey (P)

Department of Pharmaceutical Sciences, Shri Baba Mastnath University, Rohtak, Haryana, 124001, India.

Dinesh Kumar Chellappan (DK)

Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil, Kuala Lumpur, 57000, Malaysia.

Ridhima Wadhwa (R)

Faculty of Life Science and Biotechnology, South Asian University, Akbar Bhawan, Chanakyapuri, New Delhi, 110021, India.

Trudi Collet (T)

Indigenous Medicines Group, Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Australia.

Philip M Hansbro (PM)

Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia.

S Rajesh Kumar (SR)

Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077, Tamil Nadu, India.

Lakshmi Thangavelu (L)

Nanobiomedicine Lab, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Chennai, 600077, Tamil Nadu, India.

Poonam Negi (P)

School of Pharmaceutical Sciences, Shoolini University, Solan, Himachal Pradesh, India.

Kamal Dua (K)

Centre for Inflammation, Centenary Institute, Sydney, NSW, 2050 Australia; Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) & School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, NSW, 2308, Australia; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW, 2007, Australia. Electronic address: Kamal.Dua@uts.edu.au.

Saurabh Satija (S)

School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar-Delhi G.T. Road (NH-1), Phagwara, 144411, Punjab, India. Electronic address: saurabh.21958@lpu.co.in.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Dendrimères › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Systèmes de délivrance de médicaments › Vecteurs de médicaments › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Matériaux biomimétiques › Membrane artificielle › Liposomes › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Technologie, industrie et agriculture › Produits manufacturés › Nanostructures › Nanoparticules › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Sondes moléculaires › Sondes d'acide nucléique › Éléments antisens (génétique) › Oligonucléotides antisens › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Broncho-pneumopathie chronique obstructive › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Interférence par ARN › Oligonucleotide therapy: An emerging focus...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › Petit ARN interférent › Oligonucleotide therapy: An emerging focus...